Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Waters Corporation Q3 2017 Financial Results Webcast Invitation October 2, 2017 Flexion Eyes Creation of 100 New Sales Jobs to Sell Just-Approved Osteoarthritis Drug October 10, 2017 Pharma Giant Bristol-Myers Squibb Plans Layoffs, Effective Oct. 6 August 9, 2017
Flexion Eyes Creation of 100 New Sales Jobs to Sell Just-Approved Osteoarthritis Drug October 10, 2017